BRAF and ameloblastoma: According to significant evidence of activating MAPK pathway in the pathogenesis of ameloblastoma (4) and since BRAF is the most prominent activator of this pathway (23,24), high frequency of BRAF mutation in ameloblastoma in Iranian population demonstrate the possibility of MAPK pathway activation in the pathogenesis of this aggressive benign tumor.